Tamtam Try Tamtam free
Ro logo

Ro account plan

Telehealth and in-home care

At a glance

Ro is a private US telehealth company, mostly GLP-1 weight-loss programmes, with more than $3 billion in annualized revenue.

Ro is a privately held, venture-backed US telehealth company, founded as Roman in 2017, that sells GLP-1 treatments such as Wegovy and Zepbound through its Ro Body subscription service, alongside other treatments. It announced more than $3 billion in annualized revenue in November 2026, up nearly tenfold since the 2022 revamp, with a team of roughly 400 according to its CEO on a podcast. It has not raised new money from investors in years and says it can fund itself from operations. Zachariah Reitano is co-founder and CEO.

Strategic priorities

Branded GLP-1 leadership
Reitano says Ro always worked directly with Novo Nordisk and Eli Lilly and is now the largest provider of branded GLP-1 drugs in the United States. He says Ro integrates with both companies.
Protecting margins on branded drugs
Selling branded drugs has taken a toll on telehealth margins. Reitano argues Ro expects higher margins because of subscriptions and cost efficiency, and says it cut the cost of its membership plans.
AI in patient care and support
Reitano says AI will speed up customer service queries and personalise treatment; he also says AI was used to help more than 1% of the US population check their insurance for free.
Celebrity-led campaigns to reduce stigma
Ro features ambassadors including Serena Williams and Charles Barkley, and Reitano says every ambassador actually uses the product.
Patient-funded care
Reitano's thesis is that where patients pay directly, prices fall and volume rises; he predicts more than half of Americans on some form of GLP-1 within 10-15 years.

Latest results

In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022. On the podcast, Reitano put the move at about a $250 million to a $3 billion run rate, with headcount down from more than 600 to roughly 400. These are figures stated by the company and its CEO; no audited accounts were read.

Investments and deals

Own infrastructure
Ro spent four to five years building its own electronic medical records system, its own CLIA-certified lab, its own pharmacy software and its own provider network.
Ro Body (2023)
Subscription service launched in 2023 to help customers obtain GLP-1 treatments and navigate insurance.
Marketing
Digital ads, TV commercials, subway posters and influencer campaigns, plus a Super Bowl ad with Serena Williams in 2026.
Funding history
A $500 million raise at a $5 billion valuation in spring 2021; Ro has raised around $1 billion to date according to PitchBook.

Challenges and risks

Margin pressure from branded drugs
Selling branded drugs has taken a toll on telehealth companies' margins; Hims lowered its earnings guidance for the year.
Drug makers' own direct-to-consumer sales
Novo Nordisk and Eli Lilly are building their own direct-to-consumer businesses while also working with Ro.
Supply shortages
In 2024 shortages led Ro to pause advertising temporarily and to make 50,000 phone calls to pharmacies between July and August to transfer prescriptions.
Public reaction to its marketing
The Serena Williams Super Bowl ad ranked near the bottom of a USA Today survey of Super Bowl ads, though Reitano says it helped persuade more consumers to seek treatment.

What leadership says

“We were just really a zombie company.”

Zachariah Reitano, Co-Founder & CEO · Interview in a news article syndicated 2026-11-12

“sometimes the best time to raise money is when you don't need it.”

Zachariah Reitano, Co-Founder & CEO · Interview in a news article syndicated 2026-11-12, on a possible public listing

Where a supplier can help

Pharmacy and fulfilment services
Tied to supply shortages and the 50,000 pharmacy calls made to transfer prescriptions: pharmacy-network and logistics suppliers.
AI customer-support and insurance tooling
Tied to the priority on AI for customer service and personalisation: vendors of patient messaging and insurance-verification software.
Marketing and creative production
Tied to the celebrity-led campaigns and digital, TV and subway advertising: creative, media and measurement partners.
Margin and cost-efficiency programmes
Tied to margin pressure from branded drugs: suppliers that lower cost per patient served.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Ro?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Ro

What does Ro do?

Ro is a US telehealth company whose main business is GLP-1 weight-loss treatments such as Wegovy and Zepbound, sold through its Ro Body subscription service.

How large is Ro?

In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since 2022.

Is Ro publicly listed?

No. Ro is privately held and has not raised new money from investors in years; the CEO would not commit to a public listing.

Who leads Ro?

Zachariah Reitano is co-founder and CEO.

How many people work at Ro?

On the podcast Reitano said the team is roughly 400, down from more than 600.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)